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Objective: To evaluate the potential prophylactic activity of traditional polyherbal
remedy against malaria.
Methods: A traditional polyherbal remedy against malaria from Odisha, India was
evaluated for its potential prophylactic activity using in vitro hepatic cell lines assay and
the murine malaria system Plasmodium yoelii yoelii/Anopheles stephensi.
Results: The polyherbal extract inhibited the Plasmodium yoelii hepatic stages in vitro
(IC50 0.74 mg/mL), a therapeutic index of 9.54. In mice treated with the aqueous extract
(2000 mg/kg/day), peak parasitaemia values were 81% lower in the experimental
2.35% ± 0.14% as compared to controls 12.62% ± 0.52% (P < 0.001), suggesting sig-
niﬁcant prophylactic activity.
Conclusions: The observations provide a proof of concept for a traditional malaria
prophylactic remedy used by tribal populations in India.1. Introduction
Malaria, a disease caused by the parasite of the genus Plas-
modium, remains a major public health problem in tropical and
sub-tropical countries. It is the most important parasitic disease
in humans with an annual incidence of 198 million cases and
over 584000 deaths annually [1]. Nearly half (273 million) of the
high-risk population outside Africa reside in India. India con-
tributes over one ﬁfth (22.6%) of clinical episodes of Plasmo-
dium falciparum (P. falciparum) and 42% of episodes of
Plasmodium vivax globally [2,3] and around 200000 persons die
annually from malaria [4]. Nearly two-thirds of the malarialepisodes and the majority of malarial deaths in India are
observed in ﬁve states in India: Odisha, Chhattisgarh, Madhya
Pradesh, Jharkhand and West Bengal [5]. The situation of
malaria is aggravated by an increased prevalence of drug-
resistant P. falciparum, which poses a threat not only to those
living in endemic areas, but also to the millions of non-immune
travellers who visit the endemic areas [6]. There is a need for safe
and effective new drugs for both treatment and prevention of
malaria [7].
As in almost all tropical endemic countries, malaria in India
affects particularly people living in rural, remote areas, where
most often affordable modern drugs are not available and where
poor health care infrastructure cannot assure prompt and
appropriate treatment. Thus, a majority of the population still
relies on the use of traditional herbal medicines for the man-
agement of malaria. A recent ethnobotanical survey conducted
by our team revealed that in Odisha, India, there is a rich
repertoire of traditional herbal remedies used for malaria pre-
vention [8]. One polyherbal remedy (coded as TPMP74) was
selected for further investigation, as it is widely used by many
traditional healers to provide protection speciﬁcally against
malaria during the transmission season as these plants aren open access article under the CC BY-NC-ND
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population of malaria endemic areas. The selection of one over
another traditional medicine was based on its perceived value to
prevent, rather than treat the malaria infection because drugs
which are able to provide prophylactic cover by inhibiting the
liver stages have some advantages over chemotherapeutic
drugs [9]. The plants used in TPMP74 are known for their
antimalarial activity at blood stage.
Given the popular use of this polyherbal remedy as a malaria
prophylactic drug, information on its efﬁcacy and safety was
sought from in vitro and in vivo studies to explore the potential
activity against the Plasmodium hepatic stages and further to
identify the novel prophylactic drug of malaria.
2. Materials and methods
2.1. Plants and its extract preparation
The plants of TPMP74 were collected in Koraput District of
Odisha State, India, during September, 2011, by a taxonomist
who was conversant with the ﬂora of the area. The plants were
veriﬁed and authenticated by a botanist and voucher specimens
were deposited at our institute. TPMP74 was standardized and
quality control tests were done as per the standard guidelines
[10]. The shade dried plant parts were chopped into small pieces
and reduced to coarse powder. The aqueous extract was prepared
by soaking 320 g of the powdered plant material with 2.5 L of
distilled water using the Soxhlet apparatus (Borosil Glass
Works Ltd. India). The extract was concentrated at 60 C
using Rotavapor rotary evaporator and then freeze-dried to
obtain the crude extract. The percent yield of the extract was
11% w/w. The dried extract (brown solid) was stored in air tight
vial. The extract was subsequently reconstituted in culture me-
dium (in vitro) and in distilled water (in vivo) at appropriate
concentrations as necessary.
2.2. In vitro assay
2.2.1. Cells and parasites
HepG2-A16/hCD81-EGFP cells were cultured in Dulbecco
modiﬁed Eagle medium (DMEM), supplemented with 10%
foetal calf serum, 2 mmol/L L-glutamine, 100 units/mL of
penicillin and 100 mg/mL of streptomycin (all from Invitrogen,
France) [11,12]. Plasmodium yoelii yoelii (265 BY strain)
(P. yoelii yoelii) sporozoites were obtained from the dissection
of infected Anopheles stephensi mosquito salivary glands on
14th day after their infective blood meal.
2.2.2. In vitro assay for cell viability
HepG2-A16/hCD81-EGFP cells were seeded in 96-well
plates at the concentration of 25 × 103 cells per well in
200 mL medium. After incubation of the cells for 24 h at 37 C,
various concentration range of 0.039–20 mg/mL (half dilution)
of plant extracts were added, which were changed daily. After
72 h of drug exposure, the viable cells were determined by MTT
reduction assay [13]. In brief, MTT was dissolved in phosphate-
buffered saline (1× solution) at 5 mg/mL and diluted with
DMEM (without foetal calf serum) until the ﬁnal concentration
was 0.5 mg/mL. MTT solution (100 mL) was added to each well.
After incubation for 4 h, cell culture medium was removed
carefully and 100 mL dimethyl sulfoxide and ethanol (1:1) wasadded to each well and mixed thoroughly to dissolve the dark
purple crystals. Optical density change in viable cells was
quantiﬁed by measuring the optical density at 540 nm on a
FlexStation (Molecular Devices Ltd., UK). According to 50%
toxic concentration (TC50), the drug concentration at which a
50% reduction of MTT incorporation was observed, as
compared to that incorporated in the control cultures (control
wells consisted on untreated cells, they only received culture
medium), was derived from three independent experiments in
which each concentration was tested in triplicate.
2.2.3. In vitro assay for P. yoelii yoelii liver stage
inhibition
HepG2-A16/hCD81-EGFP cells were seeded in 96-well
plates at a density of 25 × 103 cells per well. After 24 h of in-
cubation, cells were pre-treated with the various concentrations
(0.039–5 mg/mL, half dilution) of plant extracts and the freeze-
dried sample was solubilised in DMEM supplemented as
described above. After 48 h of incubation, cells were inoculated
with 15000 sporozoites of P. yoelii yoelii. The treatment was
continued from the time of the infection and renewed 3 h later,
after sporozoite penetration into hepatic cells, and at 24 h post-
infection. Sporozoite-inoculated culture plates were centrifuged
for 10 min at 2000 r/min at 4 C in order to enhance the
infection rate. Culture medium containing the appropriate drug
concentration was changed daily until 48 h. Parasite quantiﬁ-
cation was done by immunoﬂuorescence analysis following the
ﬁxation of cultures with cold methanol. Intracellular parasites
were stained with a mouse polyclonal serum raised against
Plasmodium heat shock protein 70, followed by goat anti-mouse
Alexa Fluor 488 conjugate (Invitrogen, Molecular Probes) and
cell nuclei were stained with 1 mg/mL of 40,6-diamidino-2-
phenylindole (Invitrogen) [14]. Parasite numbers were counted
under a ﬂuorescence microscope with a 200× magniﬁcation.
According to IC50 values, the drug concentration at which a
50% reduction in the number of parasites was observed, as
compared to the number in the control culture medium, was
derived from three independent experiments in which each
concentration was tested in triplicate wells.
2.3. In vivo assay
2.3.1. Animals
The female animals (Swiss albino mice) used for these ex-
periments were obtained from Janvier Labs (Centre d'e´levage
Roger Janvier, France). The animals were allowed to acclimatize
for 7 days before the commencement of the experiment. The
study was carried out in strict accordance with the recommen-
dations in the guide of the Care and Use of Laboratory Animals
of the European Union “European Directive 86/609/EEC” and
of the National Institutes of Health. The protocol was approved
by the Committee on the Ethics of Animal Experiments of the
University of Pierre and Marie Curie, Paris 6, France (Permit
number: 75–1087).
2.3.2. Acute toxicity test
The LD50 of the plant aqueous extract was tested to deter-
mine the safety of the agent using Lorke's method [15]. Twelve
mice were randomized into four groups of three mice per cage
and were administered 1500, 2500 and 5000 mg/kg (0.5 mL)
of the extract orally and the fourth group received 0.5 mL of
Prakash Bangalore Nagendrappa et al./Asian Pac J Trop Biomed 2015; 5(12): 982–986984distilled water to serve as control. The mice were observed for
manifestation of physical signs of toxicity such as writhing,
decreased motor activity, paw licking, decreased body/limb
tone, respiration distress and death in the 4th hour and
subsequently for 4 days.
2.3.3. In vivo assay for activity on P. yoelii yoelii
infections
The mice were randomly divided into four groups of six mice
and administered orally with either 500, 1000, 2000 mg/kg/day
of the TPMP74 aqueous extract which were safe dosages or
distilled water 0.5 mL to the control group for three consecutive
days (Day 0–Day 2). On the fourth day, the mice were challenged
by retro-orbital injection with 5000 sporozoites of P. yoelii
yoelii. The parasitaemia levels were assessed in Giemsa-stained
thin ﬁlms made from tail-blood of each mouse for 72 h after
inoculation. The percentage of parasitaemia was determined by
counting the number of the parasitized red blood cells out of
1000 erythrocytes in random ﬁelds of the microscope.
The mean percentage suppression of parasitaemia was
calculated as:Suppression ð%Þ =Parasitaemia in control−Parasitaemia in treated
Parasitaemia in control
× 100
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Figure 1. In vitro assay for P. yoelii yoelii liver stage inhibition.
Table 1
Prophylactic effect of the polyherbal decoction on mice infected with
P. yoelii yoelii. %.
Extracts Doses Parasitaemia
(mean ± SD)
Suppression
Aqueous extract 500 mg/kg 4.38 ± 0.87 65.3
1000 mg/kg 3.30 ± 0.33 73.8
2000 mg/kg 2.35 ± 0.34 81.4
Control (distilled water) 0.5 mL 12.62 ± 1.272.4. Statistical analysis
In in vitro study, TC50 and IC50 were calculated by nonlinear
regression using log (inhibitor) vs. normalized response (variable
slope) on the GraphPad Prism 5.00 software. Each TC50 and
IC50 were expressed as a mean between three independent ex-
periments, followed by the standard deviation of the mean. In
in vivo study, mean of the percentage of parasitaemia was
calculated for each group. Percentage reductions of parasitaemia
in the treatment groups against control group were calculated.
Kruskal and Wallis test was used to determine the effect of
polyherbal extract on the median parasitaemia. Further, post-hoc
test (multiple comparisons) was conducted to demonstrate if
there was any signiﬁcant difference in median parasitaemia for
each group comparison. All the statistical analyses were done
using SPSS 18.0 (SPSS Inc., Chicago, USA).
3. Results
3.1. In vitro assay for cell viability
MTT test showed a cellular toxicity above the concentration
of 0.63 mg/mL (starting from 4% at 1.25 mg/mL). TC50 value
was (7.03 ± 0.21) mg/mL, with the highest toxicity (98%)
reached at the highest dose tested (20 mg/mL).
3.2. In vitro antimalarial activity against liver stage of
P. yoelii yoelii
The activity of the aqueous extract was assessed in a standard
bioassay of cultured HepG2-A16/hCD81-EGFP cell line infec-
ted with P. yoelii yoelii sporozoites. The extract was found to be
active against the P. yoelii yoelii liver stages. Parasite inhibitionwas observed in a dose-dependent manner, with an IC50 of
(0.73 ± 0.11) mg/mL (number of schizonts in control vials:
230 ± 19). It was important to note that the hepatic forms were
completely eliminated at concentrations of 2.5 mg/mL or
greater. Figure 1 shows the graph representing the toxic and
inhibitory concentration of the drug.
3.3. In vivo acute toxicity test
There were no manifestations of physical signs of toxicity or
any mortality in any group of mice after oral administration of
the aqueous extract even at the higher dose of 5000 mg/kg,
signifying that the oral LD50 was >5000 mg/kg. Thus the
experimental doses used (500, 1000 and 2000 mg/kg) were
within safe margins.
3.4. In vivo prophylactic activity
The aqueous extract exerted a dose-dependent prophylactic
activity resulting in signiﬁcant (P < 0.001) reduction of para-
sitaemia in extract-treated groups when compared to controls. A
suppression of parasitaemia of 65.3%, 73.8% and 81.4% was
recorded for the corresponding dose of extract (500, 1000 and
2000 mg/kg/day, respectively) (Table 1) at Day 9 post-infection,
which corresponded to the maximum level of parasitaemia
reached all along the course of the infection in the mice (peak
parasitaemia). The Kruskal and Wallis test followed by post-hoc
tests showed a signiﬁcant differences between the treated and
control groups (Figure 2). Importantly, a delay of 1 day was
observed in the appearance of parasitaemia in all treated mice (6
days), compared to all controls (5 days) which in term of parasite
liver infection was considered to denote a major liver burden
decrease. This showed the effectiveness of TPMP74 extract in
the mouse model against the P. yoelii yoelii hepatic infection.
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Figure 2. In vivo assay for activity on P. yoelii yoelii infections.
Control vs. treated 500 mg/kg: P = 0.021; Control vs. treated 1000 mg/kg:
P = 0.020; Control vs. treated 2000 mg/kg: P = 0.021; Treated 500 mg/kg
vs. treated 1000 mg/kg: P = 0.061; Treated 500 mg/kg vs. 2000 mg/kg:
P = 0.021; Treated 1000 mg/kg vs. 2000 mg/kg: P = 0.020.
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This study demonstrated the malaria prophylactic potential of
the polyherbal remedy used by traditional healers in Odisha,
India, in the murine malaria parasite P. yoelii yoelii. The pro-
phylactic assay determined that the traditional remedy was able
to reduce parasitaemia by about ﬁve times the values recorded in
control mice.
The TPMP74 extract was found to be active against the
P. yoelii yoelii liver stages with parasite inhibition in a dose-
dependent manner [IC50 of (0.73 ± 0.11) mg/mL]. MTT test
showed a cellular toxicity above the concentration of 0.63 mg/
mL i.e. IC50 > TC.
The aqueous extract tested in this study has shown 73.8%
reduction of parasitaemia at 1000 mg/kg body weight and par-
asitaemia reduction has increased to 81.4% at 2000 mg/kg body
weight. The increased reduction of parasitaemia may be due to
higher dosage of the polyherbal drug or potential synergistic
effect or potential additive effect of the plants which need to be
determined in the future experiments. Although there are some
single plant formulations, traditionally, combinations of plants
have been commonly used and it is important to understand the
logic or science behind the combinations of these formulations.
In addition to a ﬁve times reduction in peak parasitaemia in
treated as compared to control mice, a one-day delay was
observed for the ﬁrst day of patency in the treated mice (6 days
vs. 5 days in the controls-after sporozoites inoculation). Because
of the exponential increase of the asexual parasites every 24 h,
such a delay could reﬂect a dramatic reduction and/or delay in
merozoites emerging after liver stage development [16]. In order
to establish whether this effect was due to an inhibitory activity
against the hepatic parasite rather than an additional activity on
the blood stages alone, we assayed the formulation against the
in vitro hepatic stages. This clearly demonstrated that the
remedy was active at inhibiting the development of the
P. yoelii yoelii livers stages with an IC50 of (0.73 ± 0.11) mg/
mL and a therapeutic index of 9.63 which compares
favourably with that of primaquine (5.25) [17]. It should be
noted that the traditionally administered formulation was not
toxic to mice when administered at the highest concentration
tested of 5000 mg/kg body weight which signiﬁes the oralLD50 was >5000 mg/kg as per guidelines of Organization for
Economic Co-operation and Development [18].
Generally, in malaria drug discovery studies, emphasis is
given to routine screening for erythrocytic (blood) phase which
is relatively less expensive and easier to carry out compared to
pre-erythrocytic stage investigations and clinically more
demanding for the treatment of malaria. However, screening of
drugs for pre-erythrocytic phase is important to develop novel
malaria prophylactic drugs. Traditionally, the selected poly-
herbal drug is exclusively used for the prevention of malaria;
hence it was preferred to determine the antiplasmodial activity of
this drug using in vitro and in vivo methods. This is the ﬁrst
study where these two methods have been used to study a
traditionally used polyherbal malaria prophylactic drug in its
crude form.
The polyherbal extract was shown a good potential as malaria
prophylaxis against rodent parasites. This needs to be further
explored on human primary hepatocytes infected with
P. falciparum. This can also be tested on P. falciparum in vivo in
humanized mice (engrafted with human hepatocytes). Perform-
ing isobolograms of the effect of the different plant constituents
when associated together will help in understanding the syner-
gistic or additive value of each plant material. Positive controls
need to be used in the future studies.
Traditional herbal remedies are widely available and
commonly used as malaria prophylaxis by the population of
Odisha, India. In malaria endemic areas, community based trials
should be encouraged to verify the prophylactic activity which
may contribute to reduce the malaria burden. In conclusion, the
results of this study showed that the traditional herbal remedy
possesses antiplasmodial activity which justiﬁes the develop-
ment of further clinical trials in order to establish its efﬁcacy as a
malaria prophylaxis.
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